KDIGO’s 2024 Updated Guidelines Re-Emphasize Commitment to Comprehensive Testing for CKD
Mohamed Eid shares his thoughts on the updated KDIGO clinical practice guidelines, published in 2024, and the need for guidelines-directed care for CKD.
PolyMast Mastitis Tube Introduced | Boehringer Ingelheim US
Find out more about the new name in the mastitis tube market, cutting down today's regular 5-day treatment to just 3: PolyMast from Boehringer Ingelheim.
Explore the global impact of Cardiovascular- Kidney- Metabolic (CKM) syndrome, and the need for an integrated approach to manage these interconnected conditions. Insights from experts at Boehringer Ingelheim and George Washington University.
SPEVIGO approved for expanded indications in China and the US
FDA approval for the Treatment of Generalized Pustular Psoriasis (GPP) in Adults and Pediatric Patients 12 Years of Age and Older Weighing at Least 40kg
It can be hard for people living without schizophrenia to realize its burdens. Understanding these challenges can provide insights to help patients in need.
: A biosimilar is a version of a biologic medication that is made by a different company than the one that invented it, with no clinically meaningful differences in terms of safety, potency and purity.
Connecting our employees to nonprofits that help people around the world
Learn about the new online tool that we’re using to help our employees connect with nonprofits that are providing critical services to communities, choose volunteer activities in their field, and lend their expertise to those in need.
Our family-owned company condemns the ongoing military aggression against Ukraine, and have maintained our support for those in need by providing financial and in-kind donations through our Boehringer Ingelheim Cares Foundation.
Driving innovation through diversity and inclusion. Inclusive leaders and an inclusive organisation allow diversity to flourish. Diversity is the mix. Inclusion is making the mix work.